Impel Pharmaceuticals Inc (IMPLQ)
$0.02
$0.00 (0.00%)As on 05-Apr-2024 14:09EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Impel Pharmaceuticals Inc (IMPLQ)
| -- | 87.5 | -- | -- | -- | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Impel Pharmaceuticals Inc (IMPLQ)
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is... Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. Read more
-
Co-Founder and Chief Technology & Development Officer
Dr. John D. Hoekman Ph.D.
-
Co-Founder and Chief Technology & Development Officer
Dr. John D. Hoekman Ph.D.
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Impel Pharmaceuticals Inc (IMPLQ)
What is the current share price of Impel Pharmaceuticals Inc (IMPLQ) Today?
The share price of Impel Pharmaceuticals Inc (IMPLQ) is $0.02 (NASDAQ) as of 05-Apr-2024 14:09 EDT. Impel Pharmaceuticals Inc (IMPLQ) has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Impel Pharmaceuticals Inc (IMPLQ)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
What is the 52 Week High and Low of Impel Pharmaceuticals Inc (IMPLQ)?
The 52-week high and low of Impel Pharmaceuticals Inc (IMPLQ) are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of Impel Pharmaceuticals Inc (IMPLQ)?
Impel Pharmaceuticals Inc (IMPLQ) has a market capitalisation of -- as on 05-Apr-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Impel Pharmaceuticals Inc (IMPLQ)?
Before investing in Impel Pharmaceuticals Inc (IMPLQ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.